

Kibow Biotech to exhibit Its "Enteric Dialysis" Technology at ASN 2018

24 October 2018 | News

In this event, the company's personnel interact and update development with nephrology professionals on the crucial role of the gut-kidney connection, dysbiosis, and modulation of the Gut Microbiome with its innovative "Enteric Dialysis®" technology



Kibow Biotech is proud to announce its 21st year of operations as a pioneer with the use of Pro/Prebiotics in people with failing kidneys. Kibow has been participating and exhibiting at the annual meeting of the American Society of Nephrology being held from Oct 22–28, San Diego, CA.

In this event, the company's personnel interact and update development with nephrology professionals on the crucial role of the gut-kidney connection, dysbiosis, and modulation of the Gut Microbiome with its innovative "Enteric Dialysis®" technology. Although marketed and sold in the USA and several other countries as a dietary supplement product, RenadylTM is the first and only kidney health supplement with its proprietary and patented Probiotics/Prebiotics formulation researched and developed with the type of rigor applied to drug development for Kibow's revolutionary "Enteric Dialysis®" technology concept.

Recently, a new program has been initiated called **"KIDNEYX".** This program, established in April 2018, is a joint public-private partnership between the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN).

According to KidneyX announcement "For the past 50 years, advances in treatments for kidney diseases and kidney failure have been modest with few significant innovations reaching people who live with kidney diseases. Several barriers may be limiting kidney health innovation, including 1) lack of capital, 2) risks associated with early-stage research and development, and 3) low levels of meaningful input from other medical, scientific, or technological fields."

With 21 years of R&D and clinical trial expertise, Kibow Biotech's vision is to provide an inexpensive, convenient, oral kidney health supplement that could be useful for over 300 million people suffering from CKD worldwide. Preliminary consumer 3^d biennial survey data looks promising, showing not only an arresting of the decline of GFR, but stabilization and also in

majority of cases increased GFR, in all stages of kidney disease when used in conjunction with an individual's standard care of therapy.

Recently, an independent commentary by the chief R&D scientist of Kibow titled - Reality of "Enteric Dialysis ®" with Probiotics and Prebiotics to Delay the Need of Conventional Dialysis has also been published in the Journal of Nephrology and Therapeutics.

For additional validation, and in order to provide evidence sufficient to justify medical reimbursement of its kidney health supplement product, the company is planning to conduct a multi-site randomized controlled clinical study for a period of two years in USA and possibly in other countries also. Slowing the progression of CKD with an inexpensive alternative technology can help reduce the healthcare cost for patients both during dialysis and before initiation of dialysis.

This kind of multi-site clinical trial that includes a well-established kidney function endpoint will ultimately pave the way for acceptance of the kidney health supplement by all healthcare professionals, caregivers and payers. Use of such products would significantly reduce the healthcare cost of treating CKD worldwide.